IMCR:NASDAQImmunocore Holdings plc Analysis

Immunocore posted a strong first‑quarter 2026, with revenue rising 14% YoY to $106.7 million and net income turning positive at $12.97 million, lifting basic EPS to $0.26. The earnings beat has driven a recent 10% price rally, yet the stock now trades at $28.83, still below its DCF‑derived fair value of $34.47, implying more than 120% upside. Technically, the 20‑day SMA ($28.96) sits just above the current price while the 50‑day SMA ($29.96) and 200‑day SMA ($33.10) remain higher, signaling a short‑term bearish bias. The RSI at 45.8 points to neutral momentum, and the MACD histogram is positive (0.108) despite a bearish trend direction, suggesting a potential early reversal.
Valuation-wise, the stock appears significantly undervalued given its high gross margin (96.7%) and improving operating efficiency (operating margin 6.8%). However, the biotech sector carries high regulatory and execution risk, and the share price is near the identified support level of $27.56. Investors should weigh the strong pipeline and upside potential against the volatility (38% 30‑day) and the company’s elevated debt‑to‑equity ratio.